Edward Fox, MD, PhD, FAAN

Director, MS Clinic of Central Texas; Clinical Associate Professor

1984 …2019
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Bio

Edward Fox is a neurologist specializing in multiple sclerosis and neuroimmunology

Fingerprint Dive into the research topics where Edward Fox is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Multiple Sclerosis Medicine & Life Sciences
Relapsing-Remitting Multiple Sclerosis Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences
Pokeweed Mitogens Medicine & Life Sciences
Interferons Medicine & Life Sciences
Mitoxantrone Medicine & Life Sciences
Recurrence Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1984 2019

2 Citations (Scopus)

B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients

Lovett-Racke, A. E., Gormley, M., Liu, Y., Yang, Y., Graham, C., Wray, S., Racke, M. K., Shubin, R., Twyman, C., Alvarez, E., Bass, A., Eubanks, J. L. & Fox, E., Jul 15 2019, In : Journal of Neuroimmunology. 332, p. 187-197 11 p.

Research output: Contribution to journalArticle

Open Access
Multiple Sclerosis
B-Lymphocytes
T-Lymphocytes
Th1 Cells
Regulatory T-Lymphocytes

Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings

Perrone, C. M., Lisak, R. P., Meltzer, E. I., Sguigna, P., Tizazu, E., Jacobs, D., Melamed, E., Lucas, A., Freeman, L., Pardo, G., Goodman, A., Fox, E. J., Costello, K., Parsons, M. S., Zamvil, S. S., Frohman, E. M. & Frohman, T. C., Jul 1 2019, In : Neurology: Neuroimmunology and NeuroInflammation. 6, 4, e582.

Research output: Contribution to journalReview article

Open Access
Nervous System
Multiple Sclerosis

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS

Fox, E. J., Lublin, F. D., Wolinsky, J. S., Cohen, J. A., Williams, I. M., Meng, X., Ziehn, M., Kolodny, S. & Cree, B. A. C., Nov 1 2019, In : Neurology(R) neuroimmunology & neuroinflammation. 6, 6

Research output: Contribution to journalArticle

Open Access
Lymphocyte Count
Infection
Placebos
Therapeutics
Incidence

Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist

Fox, E. J., Buckle, G. J., Singer, B., Singh, V. & Boster, A., Feb 1 2019, In : Neurology: Clinical Practice. 9, 1, p. 53-63 11 p.

Research output: Contribution to journalReview article

Open Access
Lymphopenia
Lymphocyte Count
Therapeutics
Leukocytes
Lymphocyte Subsets

Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis

Fox, E., Vieira, M. C., Johnson, K., Peeples, M., Bensimon, A. G., Signorovitch, J. & Herrera, V., Mar 15 2019, In : Journal of the Neurological Sciences. 398, p. 163-170 8 p.

Research output: Contribution to journalArticle

Insurance Claim Review
Multiple Sclerosis
Databases
Recurrence
Fingolimod Hydrochloride